Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma

BACKGROUND: Surgery remains the frontline therapy for patients with localized clear cell renal cell carcinoma (ccRCC); however, 20%–40% recur. Angiogenesis inhibitors have improved survival in metastatic patients and may result in responses in the neoadjuvant setting. The impact of these agents on t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Christopher G., Ferguson, James E., Parker, Joel S., Moore, Dominic T., Whisenant, Jennifer G., Maygarden, Susan J., Wallen, Eric M., Kim, William Y., Milowsky, Mathew I., Beckermann, Kathryn E., Davis, Nancy B., Haake, Scott M., Karam, Jose A., Bortone, Dante S., Vincent, Benjamin G., Powles, Thomas, Rathmell, W. Kimryn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710285/
https://www.ncbi.nlm.nih.gov/pubmed/33208553
http://dx.doi.org/10.1172/jci.insight.132852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710285/
https://www.ncbi.nlm.nih.gov/pubmed/33208553
http://dx.doi.org/10.1172/jci.insight.132852

Ejemplares similares